137 related articles for article (PubMed ID: 33932713)
1. Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.
Ortuzar N; Karu K; Presa D; Morais GR; Sheldrake HM; Shnyder SD; Barnieh FM; Loadman PM; Patterson LH; Pors K; Searcey M
Bioorg Med Chem; 2021 Jun; 40():116167. PubMed ID: 33932713
[TBL] [Abstract][Full Text] [Related]
2. Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.
Sheldrake HM; Travica S; Johansson I; Loadman PM; Sutherland M; Elsalem L; Illingworth N; Cresswell AJ; Reuillon T; Shnyder SD; Mkrtchian S; Searcey M; Ingelman-Sundberg M; Patterson LH; Pors K
J Med Chem; 2013 Aug; 56(15):6273-7. PubMed ID: 23844629
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents.
Bart AG; Morais G; Vangala VR; Loadman PM; Pors K; Scott EE
Drug Metab Dispos; 2022 Jan; 50(1):49-57. PubMed ID: 34607808
[TBL] [Abstract][Full Text] [Related]
4. Analogues of DNA minor groove cross-linking agents incorporating aminoCBI, an amino derivative of the duocarmycins: Synthesis, cytotoxicity, and potential as payloads for antibody-drug conjugates.
Giddens AC; Lee HH; Lu GL; Miller CK; Guo J; Lewis Phillips GD; Pillow TH; Tercel M
Bioorg Med Chem; 2016 Nov; 24(22):6075-6081. PubMed ID: 27745990
[TBL] [Abstract][Full Text] [Related]
5. A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
Sato A; McNulty L; Cox K; Kim S; Scott A; Daniell K; Summerville K; Price C; Hudson S; Kiakos K; Hartley JA; Asao T; Lee M
J Med Chem; 2005 Jun; 48(11):3903-18. PubMed ID: 15916443
[TBL] [Abstract][Full Text] [Related]
6. Spirooxindoles as novel 3D-fragment scaffolds: Synthesis and screening against CYP121 from M. tuberculosis.
Davis HJ; Kavanagh ME; Balan T; Abell C; Coyne AG
Bioorg Med Chem Lett; 2016 Aug; 26(15):3735-40. PubMed ID: 27287372
[TBL] [Abstract][Full Text] [Related]
7. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents.
Wang R; Chen Y; Yang B; Yu S; Zhao X; Zhang C; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Jan; 94():103474. PubMed ID: 31859010
[TBL] [Abstract][Full Text] [Related]
9. Structural influence of indole C5-N-substitutents on the cytotoxicity of seco-duocarmycin analogs.
Choi T; Ma E
Arch Pharm Res; 2011 Mar; 34(3):357-67. PubMed ID: 21547666
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
11. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.
Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM
Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796
[TBL] [Abstract][Full Text] [Related]
12. DNA sequence selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145.
Kiakos K; Sato A; Asao T; McHugh PJ; Lee M; Hartley JA
Mol Cancer Ther; 2007 Oct; 6(10):2708-18. PubMed ID: 17938264
[TBL] [Abstract][Full Text] [Related]
13. How can the potential of the duocarmycins be unlocked for cancer therapy?
Jukes Z; Morais GR; Loadman PM; Pors K
Drug Discov Today; 2021 Feb; 26(2):577-584. PubMed ID: 33232841
[TBL] [Abstract][Full Text] [Related]
14. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
15. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Li A; Yadav R; White JK; Herroon MK; Callahan BP; Podgorski I; Turro C; Scott EE; Kodanko JJ
Chem Commun (Camb); 2017 Mar; 53(26):3673-3676. PubMed ID: 28304025
[TBL] [Abstract][Full Text] [Related]
16. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
Potęga A; Fedejko-Kap B; Mazerska Z
Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
[TBL] [Abstract][Full Text] [Related]
17. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
Tietze LF; Krewer B
Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
[TBL] [Abstract][Full Text] [Related]
18. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
[TBL] [Abstract][Full Text] [Related]
19. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity.
Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D
J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors.
Guo J; Zhao F; Yin W; Zhu M; Hao C; Pang Y; Wu T; Wang J; Zhao D; Li H; Cheng M
Eur J Med Chem; 2018 Jul; 155():197-209. PubMed ID: 29886323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
